NAGE Q1 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+30.7% YoY

Gross Profit

$14M59.9% margin

Operating Income

-$2M-8.7% margin

Net Income

-$2M-8.4% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+7.4%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$54M

Total Liabilities

$26M

Stockholders' Equity

$28M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$17M	+30.7%
Gross Profit	$14M	$11M	+28.4%
Operating Income	-$2M	-$8M	+74.5%
Net Income	-$2M	-$8M	+75.4%